Melanoma and Mastocytosis
There are numerous cases reports and studies confirming the enhanced incidence of melanoma among patients with mastocytosis, especially with systemic mastocytosis. These two diseases are arising from two different types of cells; melanoma arises from neural crest cells and mastocytosis from hematopoietic stem cells. But there are a lot of similarities between the two diseases. The most important and significant is the dependence of the growth factor receptor câ€KIT and câ€KIT ligand (stem cell factor) for their growth and development. Also, expression of the STAT3 (signal transducer and activator of transcription 3) and transcription factors MITF (microphthalmiaâ€associated transcription factor) make the connection between melanoma and mastocytosis.
Plum Analytics Artifact Widget Block
Capo A, Goteri G, Mozzicafreddo G, Serresi S, Giacchetti A. Melanoma and mastocytosis: is really only a coincidence? Clin Exp Dermatol. 2019; 44(1):76-7. https://doi.org/10.1111/ced.13717 PMid:30178486
Molderings GJ, Zienkiewicz T, Homann J, Menzen M, Afrin LB.Risk of solid cancer in patients with mast cell activation syndrome: Results from Germany and USA. F1000Res. 2017; 6:1889. https://doi.org/10.12688/f1000research.12730.1 PMid:29225779 PMCid:PMC5710302
Broesby-Olsen S et al. Risk of solid cancer, cardiovascular disease, anaphylaxis, osteoporosis and fractures in patients with systemic mastocytosis: A nationwide population-based study. Am J Hematol. 2016; 91(11):1069-75. https://doi.org/10.1002/ajh.24490 PMid:27428296
Phung B, et al. KITD816V Induces SRC-Mediated Tyrosine Phosphorylation of MITF and Altered Transcription Program in Melanoma. Mol Cancer Res. 2017; 15(9):1265-1274. https://doi.org/10.1158/1541-7786.MCR-17-0149 PMid:28584020
HÃ¤gglund H, Sander B, Ahmadi A, GÃ¼len T, Nilsson G. Analysis of V600E BRAF and D816V KIT mutations in systemic mastocytosis.Med Oncol. 2014; 31(8):123. https://doi.org/10.1007/s12032-014-0123-4 PMid:25034364
Abbaspour Babaei M, Kamalidehghan B, Saleem M, Huri HZ, Ahmadipour F Receptor tyrosine kinase (c-Kit) inhibitors: a potential therapeutic target in cancer cells. Drug Des Devel Ther. 2016; 10:2443-59. https://doi.org/10.2147/DDDT.S89114 PMid:27536065 PMCid:PMC4975146
Ehara Y, Yoshida Y, Tahira M, Yamamoto O. The expression of melanoma inhibitory activity on mast cells in child patients with cutaneous mastocytosis. Yonago Acta Med. 2014; 57(3):99-101.
Heldin CH, Lennartsson J Structural and functional properties of platelet-derived growth factor and stem cell factor receptors. Cold Spring Harb Perspect Biol. 2013; 5(8):a009100. https://doi.org/10.1101/cshperspect.a009100 PMid:23906712 PMCid:PMC3721287
Donati P, Paolino G, Donati M, Panetta C. Cutaneous mastocytosis combined with eruptive melanocytic nevi and melanoma. Coincidence or a linkage in the pathogenesis? J Dermatol Case Rep. 2014; 8(3):70-4. https://doi.org/10.3315/jdcr.2014.1179 PMid:25324908 PMCid:PMC4195503
Copyright (c) 2019 Aleksandra Vojvodic, Tatjana Vlaskovic-Jovicevic, Petar Vojvodic, Jovana Vojvodic, Mohamad Goldust, Zorica Peric-Hajzler, Dusica Matovic, Goran Sijan, Nenad Stepic, Uwe Wollina, Massimo Fioranelli, Van Thuong Nguyen, Michael Tirant, Torello Lotti (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All rights reserved.